14-49633687-C-T
Variant summary
Our verdict is Benign. Variant got -7 ACMG points: 2P and 9B. PM2BP4_StrongBP6BS1
The NM_018139.3(DNAAF2):c.1463G>A(p.Gly488Glu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000663 in 1,606,692 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_018139.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -7 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
DNAAF2 | NM_018139.3 | c.1463G>A | p.Gly488Glu | missense_variant | 1/3 | ENST00000298292.13 | NP_060609.2 | |
DNAAF2 | NM_001083908.2 | c.1463G>A | p.Gly488Glu | missense_variant | 1/2 | NP_001077377.1 | ||
DNAAF2 | NM_001378453.1 | c.-409G>A | 5_prime_UTR_variant | 1/2 | NP_001365382.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
DNAAF2 | ENST00000298292.13 | c.1463G>A | p.Gly488Glu | missense_variant | 1/3 | 1 | NM_018139.3 | ENSP00000298292 | P2 | |
DNAAF2 | ENST00000406043.3 | c.1463G>A | p.Gly488Glu | missense_variant | 1/2 | 1 | ENSP00000384862 | A2 |
Frequencies
GnomAD3 genomes AF: 0.000500 AC: 76AN: 152148Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.000713 AC: 176AN: 246798Hom.: 0 AF XY: 0.000716 AC XY: 96AN XY: 134108
GnomAD4 exome AF: 0.000680 AC: 989AN: 1454426Hom.: 0 Cov.: 92 AF XY: 0.000691 AC XY: 499AN XY: 722438
GnomAD4 genome AF: 0.000499 AC: 76AN: 152266Hom.: 0 Cov.: 33 AF XY: 0.000497 AC XY: 37AN XY: 74460
ClinVar
Submissions by phenotype
Primary ciliary dyskinesia Benign:2
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 24, 2021 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 26, 2024 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Sep 02, 2015 | Variant classified as Uncertain Significance - Favor Benign. The p.Gly488Glu var iant in DNAAF2 has not been previously reported in individuals with pulmonary di sease, but has been identified in 0.13% (86/64746) of European chromosomes by th e Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org; dbSNP rs20 0121200). Glycine (Gly) at position 488 is not conserved evolution and 3 mammals (brush tailed rat, star nosed mole, opossum) carry a glutamic acid (Glu) at thi s position, supporting that this change may be tolerated. Additional computatio nal prediction tools suggest that the p.Gly488Glu variant may not impact the pro tein, though this information is not predictive enough to rule out pathogenicity . In summary, while the clinical significance of the p.Gly488Glu variant is unce rtain, its frequency suggests that it is more likely to be benign. - |
Primary ciliary dyskinesia 10 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 12, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. - |
DNAAF2-related disorder Benign:1
Benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Aug 07, 2019 | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at